oxazolidin-2-one has been researched along with fidaxomicin in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bruyère, T; Caspers, P; Keck, W; Knezevic, A; Locher, HH; Pfaff, P; Ritz, D; Schroeder, S | 1 |
Clozel, M; Enderlin-Paput, M; Locher, HH; Pfaff, P; Ritz, D; Seiler, P; Weiss, M | 1 |
Alam, MJ; Bassères, E; Endres, BT; Garey, KW | 1 |
Birchall, S; Corbett, D; Locher, HH; Skinner, K; Thommes, P | 1 |
1 review(s) available for oxazolidin-2-one and fidaxomicin
Article | Year |
---|---|
Cadazolid for the treatment of Clostridium difficile.
Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Lipopeptides; Oxazolidinones; Peptides, Cyclic; Treatment Outcome | 2017 |
3 other study(ies) available for oxazolidin-2-one and fidaxomicin
Article | Year |
---|---|
Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; DNA Gyrase; Drug Resistance, Bacterial; Fidaxomicin; Fluoroquinolones; Linezolid; Microbial Sensitivity Tests; Oxazolidinones; Protein Biosynthesis; Recombinant Proteins; RNA; Subcellular Fractions; Transcription, Genetic; Vancomycin | 2014 |
Cadazolid Does Not Promote Intestinal Colonization of Vancomycin-Resistant Enterococci in Mice.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Clostridioides difficile; Colony Count, Microbial; Diarrhea; Enterocolitis, Pseudomembranous; Fidaxomicin; Intestines; Metronidazole; Mice; Microbial Sensitivity Tests; Oxazolidinones; Streptococcal Infections; Treatment Outcome; Vancomycin; Vancomycin Resistance; Vancomycin-Resistant Enterococci | 2016 |
Time-kill kinetics of cadazolid and comparator antibacterial agents against different ribotypes of Clostridium difficile.
Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Kinetics; Microbial Sensitivity Tests; Oxazolidinones; Ribotyping; Vancomycin | 2018 |